$ERAS News

Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Mizuho Maintains Outperform on Erasca, Lowers Price Target to $26

Erasca (NASDAQ:ERAS) Beats Q1 Estimates on Promising ERAS-0015 Data

Erasca Q1 EPS $(0.60) Misses $(0.22) Estimate

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca (ERAS) Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity

Erasca (ERAS) Recoups 16.9% Gain on Cancer Treatment Optimism

Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results

Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges

Erasca stock sinks 50% after patient death in drug trial

Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial

Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its Value

Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data

Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight

Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 - Slideshow

Erasca shares are trading lower. The company announced preliminary Phase 1 dose escalation data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.

Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript

Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals